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of a protease inhibitor and antibiotics, depending on the
patient’s condition.
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Clinical questions
CQ1. Is adequate ﬂuid replacement crucial in the
management of acute pancreatitis?
CQ2. Is pain control by analgesia crucial in acute
pancreatitis?
CQ3. Are nasogastric suction and H2 blockers
necessary?
CQ4. Is the continuous intravenous application of a
large dose of a protease inhibitor useful for
severe acute pancreatitis?
CQ5. Is enteral nutrition superior to total parenteral
nutrition as nutritional support in severe acute
pancreatitis?
CQ6. Is prophylactic antibiotic administration
necessary for the prevention of infections in
severe acute pancreatitis?
CQ7. Is blood puriﬁcation therapy useful in severe
acute pancreatitis?
CQ8. Does continuous regional arterial infusion of
protease inhibitors and antibiotics reduce the
mortality rate and incidence of infectious com-
plications in acute necrotizing pancreatitis?
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Abstract
The basic principles of the initial management of acute pan-
creatitis are adequate monitoring of vital signs, ﬂuid replace-
ment, correction of any electrolyte imbalance, nutritional
support, and the prevention of local and systemic complica-
tions. Patients with severe acute pancreatitis should be trans-
ferred to a medical facility where adequate monitoring and
intensive medical care are available. Strict cardiovascular and
respiratory monitoring is mandatory for maintaining the car-
diopulmonary system in patients with severe acute pancreati-
tis. Maximum ﬂuid replacement is needed to stabilize the
cardiovascular system. Prophylactic antibiotic administration
is recommended to prevent infectious complications in pa-
tients with necrotizing pancreatitis. Although the efﬁcacy of
the intravenous administration of protease inhibitors is still a
matter of controversy, there is a consensus in Japan that a
large dose of a synthetic protease inhibitor should be given to
patients with severe acute pancreatitis in order to prevent
organ failure and other complications. Enteral feeding is
superior to parenteral nutrition when it comes to the nutri-
tional support of patients with severe acute pancreatitis.
The JPN Guidelines recommend, as optional measures, blood
puriﬁcation therapy and continuous regional arterial infusionK. Takeda et al.: Medical management of acute pancreatitis 43
Introduction
In 70% to 80% of patients with acute pancreatitis, the
disease is mild and promptly responds to supportive
measures alone. The remaining 20%–30% of patients
have a severe form of pancreatitis and develop shock,
respiratory failure, and infectious complications. Pa-
tients with severe acute pancreatitis should be trans-
ferred to a medical facility where adequate monitoring
and intensive medical care is available.1
The basic principles of the initial management of
acute pancreatitis are adequate monitoring of vital
signs, ﬂuid replacement, correction of any electrolyte
imbalance, nutritional support, and the prevention of
local and systemic complications. In mild acute pancre-
atitis, adequate ﬂuid replacement, pain relief, and moni-
toring of vital signs is enough to ensure recovery from
the disease. In severe acute pancreatitis, strict cardio-
vascular and respiratory monitoring is mandatory for
maintaining the cardiopulmonary system. Maximum
ﬂuid replacement is needed to stabilize the cardiovas-
cular system, and adjustment of any electrolyte and
acid-base imbalance is also required. Oxygen is admin-
istered, as needed, to maintain at least 95% oxygen
saturation. Prophylactic antibiotic administration is
recommended to prevent infectious complications in
patients with necrotizing pancreatitis. Although the efﬁ-
cacy of intravenous protease inhibitor administration is
still a matter of controversy, there is a consensus in
Japan that a large dose of a synthetic protease inhibitor
should be given to patients with severe acute pancreati-
tis in order to prevent organ failure and other complica-
tions. Nutritional support is crucial in patients with
severe acute pancreatitis. Enteral feeding is superior to
parenteral nutrition for the nutritional management of
patients with severe acute pancreatitis.
Principles of medical management for
acute pancreatitis
Clinical question (CQ) 1. Is adequate ﬂuid replace-
ment crucial in the management of acute pancreatitis?
An adequate volume of intravenous ﬂuid should be
promptly administered to correct the volume deﬁcit
and maintain basal ﬂuid requirements (Recommenda-
tion A)
Increased vascular permeability in acute pancreatitis
causes the loss of intravenous ﬂuid and reduces plasma
volume. In severe cases, in patients with massive ascites,
pleural effusion, and retroperitoneal and mesenteric
edema, circulating plasma volume decreases markedly.
Hypovolemia may lead to shock and acute renal failure,
and, because hypovolemic shock may impair the pan-
creatic microcirculation and promote pancreatic is-
chemia and necrosis, restoration and maintenance of
plasma volume is crucial in severe acute pancreatitis.
An adequate volume of intravenous ﬂuid should be
promptly administered to correct the volume deﬁcit and
maintain basal ﬂuid requirements. Balanced electrolyte
solutions, such as Ringer’s lactate, are recommended to
stabilize the cardiovascular system. The infusion vol-
ume should be decided while monitoring blood pres-
sure, heart rate, hematocrit, and urine output. Calcium
and potassium chloride should be replaced if deﬁcien-
cies arise. Hyperglycemia is managed with insulin as
needed. In patients with severe acute pancreatitis,
continuous monitoring of central venous pressure or
pulmonary wedge pressure, blood gas analysis, and
electrolyte measurement is crucial to determining the
adequate volume that must be replaced. Oxygen is ad-
ministered as needed to maintain at least 95% oxygen
saturation. Fluid infusion may be complicated by pul-
monary edema due to an increase in lung water and is
an indication for artiﬁcial ventilation.
CQ2. Is pain control by analgesia crucial in acute
pancreatitis?
Acute pancreatitis is accompanied by persistent severe
abdominal pain. Analgesia is crucial (Recommenda-
tion A)
The pain associated with acute pancreatitis may cause
anxiety in patients and adversely affect their clinical
course; this may include respiratory distress, which
should be relieved shortly after it develops. The non-
narcotic analgesic buprenorphine has an effect superior
to procaine, and, unlike procaine, it does not exacerbate
the pathology of acute pancreatitis by including contract-
ing the sphincter of Oddi (Level 1b).2 Buprenorphine has
an analgesic effect similar to that of pethidine (Level 1b).3
CQ3. Are nasogastric suction and H2 blockers
necessary?
Nasogastric suction through a nasogastric tube is un-
necessary in patients with acute pancreatitis unless the
disease is associated with paralytic ileus and/or
frequent vomiting. H2 blockers are also unnecessary
unless a stress ulcer develops (Recommendation D)
There are no deﬁnitive studies in humans to support the
opinion that nasogastric suction is useful to the pancreas
at rest in patients with acute pancreatitis. Randomized
controlled trials (RCTs) in patients with mild to moder-
ate acute pancreatitis have shown no ameliorating ef-
fect of gastric suction on the clinical course by, for
example, alleviating pain or shortening the hospital
stay.4–11 Rather, there are some reports claiming that44 K. Takeda et al.: Medical management of acute pancreatitis
nasogastric suction may prolong the period of abdomi-
nal pain and nausea.7–10 The placement of a nasogastric
tube in patients with acute pancreatitis is unnecessary
unless the disease is associated with paralytic ileus and/
or frequent vomiting. There are no reports suggesting
that cimetidine, an H2 blocker, might ameliorate the
clinical course of acute pancreatitis;10,12–15  however,
treatment with an H2 blocker should be considered
when a patient with acute pancreatitis develops a stress
ulcer or acute gastric mucosal lesion.
CQ4. Is the continuous intravenous application of a
large dose of a protease inhibitor useful for severe
acute pancreatitis?
Continuous intravenous infusion of a large dose of a
protease inhibitor reduces the incidence of complica-
tions in the early phase of severe acute pancreatitis
(Recommendation B)
In the 1960s, the protease inhibitor aprotinin was widely
used to treat severe acute pancreatitis, but the drug failed
to demonstrate clinical efﬁcacy in three RCTs (Level
1b).16–18 The efﬁcacy of the synthetic protease inhibitor
gabexate mesilate was investigated in ﬁve RCTs (Level
1b),19–23 but a metaanalysis24 of four of them19–22 showed
no reduction in the frequency of surgical intervention or
in the mortality rate, although the incidence of complica-
tions was reduced (Level 1a). However, the remaining
RCT (Level 1b),23 the results of which were published in
2000, showed that continuous intravenous administra-
tion of gabexate mesilate (2400mg/day) for 7 days
signiﬁcantly reduced the frequency of complications and
the mortality rate. Although the efﬁcacy of protease
inhibitors in severe acute pancreatitis is still a matter of
controversy, the consensus in Japan, as outlined in the
JPN Guidelines, recommends the continuous infusion of
an intravenous protease inhibitor in the early phase of
severe acute pancreatitis. Nafamostat mesilate (NM), a
synthetic serine protease inhibitor, and gabexate
mesilate (GM) are widely used in Japan. NM has a longer
half-life than GM (55s for GM vs 23min for NM) and is
used in patients with disseminated intravasucular coagu-
lation (DIC) and during hemodialysis, because of its
potent anti-coagulant effect.
CQ5. Is enteral nutrition superior to total parenteral
nutrition as nutritional support in severe acute
pancreatitis?
Enteral nutrition starting in the early phase of severe
acute pancreatitis is superior to total parenteral nutri-
tion unless ileus is present (Recommendation A)
There is no evidence from human studies to show that
parenteral nutrition is clinically more efﬁcacious in
acute pancreatitis than enteral nutrition. Recent clinical
trials of nutritional management in acute pancreatitis
have shown that enteral nutrition is more useful than
total parenteral nutrition in terms of ability to alleviate
the inﬂammatory response and reduce the incidence of
infection, frequency of surgery, and medical costs. A
metaanalysis (Level 1a)31 of six RCTs (263 cases; Level
1b)25–30 — which compared two methods of nutritional
management of acute pancreatitis (total parenteral nu-
trition and enteral nutrition) — showed that enteral
nutrition reduced the frequency of infection, surgery,
and the length of hospital stay. However, there was no
difference in the mortality rate or incidence of compli-
cations other than infection.
Enteral nutrition has been provided through feeding
tubes inserted from the ligament of Treitz to the distal
jejunum, and the infusion of nutrients into the stomach
and duodenum has been avoided because of the possi-
bility of stimulating pancreatic exocrine secretion. How-
ever, a report from Glasgow (Level 1b),32 comparing
nasogastric to nasojejunal feeding, found no difference
in changes in the Acute Physiology and Chronic Health
Evaluation (APACHE) II score, C-reactive protein
(CRP) level, visual analogue scale (VAS) pain score,
doses of analgesic administered, or mortality rates be-
tween the two methods. Nasogastric feeding is easier to
perform and it is easier to locate the tube than it is to
locate a nasojejunal tube. Nasogastric nutrition should
be investigated further.
CQ6. Is prophylactic antibiotic administration nec-
essary for the prevention of infection in severe acute
pancreatitis?
Prophylactic administration of broad-spectrum anti-
biotics with good tissue penetration is necessary to
prevent infection in severe acute pancreatitis (Recom-
mendation A)
Pancreatic and extrapancreatic infections are a deter-
mining factor leading to death in severe acute pancrea-
titis. The mortality rate of patients with infected
pancreatic necrosis or sepsis is extremely high, and anti-
biotic prophylaxis has been recommended to prevent
infectious complications in severe acute pancreatitis.
Three RCTs of the antibiotic ampicillin conducted in
the 1970s showed that it did not reduce the frequency of
infectious complications (Level 1b).33–35 A human study
investigating pancreatic tissue penetration by antibiot-
ics demonstrated that broad-spectrum antibiotics such
as ciproﬂoxacin, oﬂoxacin, imipenem, and peﬂoxacin
provided sufﬁcient tissue concentration in the pan-
creas.36 Four RCTs (Level 1b)37–40 of the prophylactic
effect of antibiotics demonstrated that broadspectrum
antibiotics with good pancreatic tissue penetration de-
creased the incidence of infectious complications andK. Takeda et al.: Medical management of acute pancreatitis 45
the mortality rate. A metaanalysis of those RCTs
showed that prophylactic antibiotic administration sig-
niﬁcantly improved the mortality rate in patients with
severe acute pancreatitis (Level 1a).41 An RCT compar-
ing peﬂoxacin with imipenem reported that imipenem
signiﬁcantly lowered the incidence of pancreatic infec-
tion (Level 1b).42 An RCT investigating the usefulness
of prophylactic imipenem administration within 48h
after onset showed that the early administration of
imipenem decreased the frequency of surgical interven-
tion and the number of organs that failed (Level 1b).43
A comparison between meropenem and imipenem
showed no difference in the occurrence of pancreatic
infection, complications, or mortality rates (Level 1b).44
On the other hand, a placebo-controlled, double-blind
trial of ciproﬂoxacin + metronidazole in patients with
predicted severe acute pancreatitis showed that prophy-
lactic administration of these antibiotics did not prevent
pancreatic infection (Level 1b).45
Selective digestive decontamination (SDD) has also
been reported as a means of antibiotic prophylaxis in
severe acute pancreatitis (Level 1b).46 Although SDD
was reported in the 1980s as a method of preventing
respiratory tract infection in patients with multiple
trauma,47 only one RCT assessed SDD in severe acute
pancreatitis.46 In that trial, antibiotics were given orally,
enterally, and intravenously, as well as being applied
topically to the gums and tracheotomy site. SDD signiﬁ-
cantly reduced the frequency of infectious pancreatic
complications compared with that in the control groups,
and multivariate analysis with severity assessment dem-
onstrated a reduced mortality rate for SDD. In principle,
SDD offers comprehensive infection management, not
only by the enteral administration of nonabsorptive
agents but also by the prevention of systemic infection
through sterilization of the oral cavity, as well as by
intravenous antibiotic administration and continuous
surveillance cultures of the oral cavity and rectum.
Although the prophylactic application of broad-
spectrum antibiotics reduces the incidence of infectious
complications in severe acute pancreatitis, fungal infec-
tion in pancreatic necrosis is increasing.48–53 The mortal-
ity rate of infected pancreatic necrosis complicated by
fungal infection is higher than the mortality rate in the
absence of fungal infection (Level 2b).48–53  A human
study reported that the antifungal agent ﬂuconazole had
good penetration into pancreatic tissue (Level 2b),54
and clinical studies have demonstrated that the prophy-
lactic administration of ﬂuconazole reduced the inci-
dence of fungal infection in patients with severe acute
pancreatitis (Level 2b).52–55 However, there have been
no reliable RCTs of the prophylactic administration of
antifungal agents in patients with pancreatic necrosis,
and the efﬁcacy of antifungal agents has yet to be inves-
tigated in an RCT.
CQ7. Is blood puriﬁcation therapy useful in severe
acute pancreatitis?
Blood puriﬁcation therapy may prevent the develop-
ment of multiple organ failure in severe acute pancre-
atitis (Recommendation C)
The activation of proinﬂammatory cytokines in severe
acute pancreatitis is a predominant factor leading to
multiple organ failure. Blood puriﬁcation therapy, par-
ticularly continuous hemodiaﬁltration (CHDF), should
inhibit the systemic inﬂammatory response by removing
humoral mediators. CHDF with a polymethyl-
methacrylate (PMMA) membrane removes various
cytokines from the bloodstream and is widely used in
Japan for blood puriﬁcation therapy in patients with
severe acute pancreatitis complicated by multiple organ
failure. A national survey of the usefulness of CHDF in
severe acute pancreatitis suggested that it may prevent
the progress of multiple organ failure,56 but its ability to
reduce the mortality rate is still unknown.
CQ8. Does continuous regional arterial infusion of
protease inhibitors and antibiotics reduce the mortal-
ity rate and incidence of infectious complications in
acute necrotizing pancreatitis?
Continuous regional arterial infusion of protease in-
hibitors and antibiotics may possibly reduce the mor-
tality rate and incidence of infectious complications in
necrotizing pancreatitis (Recommendation C)
The protease inhibitors used to treat acute necrotizing
pancreatitis cannot easily reach the pancreas when ad-
ministered intravenously, and, because of ischemia57,58
or impaired microcirculation, they hardly penetrate into
pancreatic tissue. Administration through a catheter
placed in one of the arteries that supply the inﬂamed
area of the pancreas, however, dramatically increases
the tissue concentration of the protease inhibitor. A
clinical study of continuous regional arterial infusion
(CRAI) of a protease inhibitor and/or an antibiotic
demonstrated that CRAI of nafamostat mesilate and
imipenem/cilastatin was effective in reducing the mor-
tality rate and preventing the development of pancre-
atic infection in acute necrotizing pancreatitis.59 A
nationwide survey of CRAI therapy in acute necrotiz-
ing pancreatitis reported that severe pain disappeared
in a short period of time after the initiation of CRAI of
a protease inhibitor; that the frequency of infected pan-
creatic necrosis in the group treated with both a pro-
tease inhibitor and antibiotic via CRAI was signiﬁcantly
lower than that in the group treated with the protease
inhibitor alone; and that the mortality rate was signiﬁ-
cantly lower in the group in which CRAI of the protease
inhibitor was started within 2 days after onset than that46 K. Takeda et al.: Medical management of acute pancreatitis
in the group in which it was started 3 or more days after
onset.60  A historical study, comparing intravenous
administration and CRAI of a protease inhibitor and
antibiotic, revealed a signiﬁcantly higher cumulative
survival rate in the CRAI group.61 In a clinical study in
which arterial infusion was performed after conﬁrming,
by computed tomography (CT) arteriography, that the
drug had reached the site of inﬂammation in the pan-
creas, the APACHE II score and the CT severity index
were improved in all subjects.62 CRAI of the protease
inhibitor nafamostat also prevented pancreatic necrosis
in patients with severe acute pancreatitis associated
with nonocclusive mesenteric ischemia (NOMI).63 Al-
though the efﬁcacy of CRAI of a protease inhibitor and
the optimal timing is still being debated, CRAI therapy
is given Recommendation C in the JPN Guidelines. The
usefulness of CRAI of a protease inhibitor should be
investigated further.
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